CORCEPT THERAPEUTICS INCORPORATED
NASDAQ: CORT (Corcept Therapeutics Incorporat)
Last update: 8 hours ago69.59
2.16 (3.20%)
| Previous Close | 67.43 |
| Open | 67.43 |
| Volume | 1,208,995 |
| Avg. Volume (3M) | 1,516,134 |
| Market Cap | 7,341,953,536 |
| Price / Earnings (TTM) | 56.58 |
| Price / Earnings (Forward) | 41.67 |
| Price / Sales | 11.54 |
| Price / Book | 10.65 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2025 - 5 May 2025 |
| Profit Margin | 20.92% |
| Operating Margin (TTM) | 13.89% |
| Diluted EPS (TTM) | 1.23 |
| Quarterly Revenue Growth (YOY) | 34.30% |
| Quarterly Earnings Growth (YOY) | -1.90% |
| Total Debt/Equity (MRQ) | 1.02% |
| Current Ratio (MRQ) | 3.35 |
| Operating Cash Flow (TTM) | 198.07 M |
| Levered Free Cash Flow (TTM) | 183.85 M |
| Return on Assets (TTM) | 11.71% |
| Return on Equity (TTM) | 23.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Corcept Therapeutics Incorporat | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.5 |
| Average | 0.50 |
|
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.44% |
| % Held by Institutions | 81.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ingalls & Snyder Llc | 31 Dec 2024 | 8,099,747 |
| Parallel Advisors, Llc | 31 Mar 2025 | 3,972,416 |
| Arrowstreet Capital, Limited Partnership | 31 Dec 2024 | 1,644,942 |
| Jacobs Levy Equity Management, Inc | 31 Dec 2024 | 1,376,881 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 150.00 (Truist Securities, 115.55%) | Buy |
| 150.00 (HC Wainwright & Co., 115.55%) | Buy | |
| Median | 146.00 (109.80%) | |
| Low | 131.00 (Piper Sandler, 88.25%) | Buy |
| Average | 143.25 (105.85%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 99.94 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 03 Apr 2025 | 131.00 (88.25%) | Buy | 79.37 |
| 27 Feb 2025 | 78.00 (12.09%) | Buy | 59.85 | |
| Canaccord Genuity | 01 Apr 2025 | 142.00 (104.05%) | Buy | 91.93 |
| 30 Jan 2025 | 130.00 (86.81%) | Buy | 69.90 | |
| HC Wainwright & Co. | 31 Mar 2025 | 150.00 (115.55%) | Buy | 114.22 |
| 27 Feb 2025 | 115.00 (65.25%) | Buy | 59.85 | |
| Truist Securities | 31 Mar 2025 | 150.00 (115.55%) | Buy | 114.22 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |